OrbitonOpen research workspace →
Atyr Pharma Inc. logo

Atyr Pharma Inc.

NASDAQ:ATYRLive AI agent

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

Investor website: https://atyrpharma.com/

About

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Their lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), targeting immune-mediated disorders that cause chronic inflammation and fibrosis of the lungs. The company is also investigating efzofitimod in pulmonary sarcoidosis and systemic sclerosis-related ILD, with a pipeline of additional therapeutic candidates derived from their tRNA synthetase platform.

Verified company data

Cash position
$58.9 million
Shares outstanding
98,051,212
Projects
["Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. We are currently investigating efzofitimod in pulmonary sarcoidosis, a major form of ILD, and systemic sclerosis (SSc, or scleroderma)-related ILD. We recently reported results from the Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, and the Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with SSc-ILD is ongoing.","ATYR1923-C-005: STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF EFZOFITIMOD IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)-RELATED ILD (SSC-ILD) We are currently conducting a Phase 2 clinical trial called EFZO-CONNECT™ that is investigating the efficacy, safety and tolerability of efzofitimod in patients with systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease (ILD). SSc is a chronic, progressive autoimmune disease characterized by inflammation and fibrosis of connective tissues throughout the body, including the skin and other internal organs. SSc that occurs in the lungs is a form of ILD called SSc-ILD. ILD is the primary cause of death in patients with SSc. Efzofitimod may help resolve inflammation and prevent the progression of fibrosis in patients with SSc-ILD. In an animal model of SSc, efzofitimod significantly reduced lung and skin fibrosis, and efzofitimod has also been shown to inhibit cytokines central to the immune pathology of SSc-ILD, including interleukin-6 (IL-6), in both animal and humans. This is Phase 2, multicenter, randomized, double-blind, placebo-controlled proof-of-concept study of intravenous (IV) efzofitimod 270 mg and 420 mg versus placebo in patients with limited or diffuse SSc-ILD. This is a 28-week study with patients receiving either efzofitimod or placebo once a month for a total of 6 doses. The study enrolled 23 patients (adults) with SSc and ILD with progressive disease on background mycophenolate therapy at multiple centers throughout the United States. The purpose of this study is to evaluate the efficacy of multiple IV doses of efzofitimod on pulmonary, cutaneous and systemic manifestations in patients with SSc-ILD. The study will also assess the safety and tolerability of multiple doses of IV efzofitimod in patients with SSc-ILD.","ATYR1923-C-004: EFFICACY AND SAFETY OF INTRAVENOUS EFZOFITIMOD IN PATIENTS WITH PULMONARY SARCOIDOSIS In September 2025, we announced topline results from the Phase 3 EFZO-FIT™ study evaluating efzofitimod in patients with pulmonary sarcoidosis, which is a major form of interstitial lung disease (ILD). EFZO-FIT™ was a global Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo in 268 patients with symptomatic pulmonary sarcoidosis in the United States, Europe, Japan and Brazil. This was a 52-week study with patients receiving either efzofitimod or placebo once a month for a total of 12 doses. The study enrolled adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroids, with or without immunosuppressant therapy, who underwent a protocol-guided oral corticosteroid taper. The purpose of the study was to evaluate whether efzofitimod treatment could reduce patients’ dose of oral corticosteroid compared to placebo. The study also designed to evaluate if efzofitimod could improve symptoms and lung function compared to placebo when steroids were reduced.","ATYR1923-C-002: Investigational Trial of ATYR1923 for the Treatment of Pulmonary Sarcoidosis In September 2021, we announced positive results from a Phase 1b/2a clinical trial evaluating efzofitimod (ATYR1923) in patients with pulmonary sarcoidosis. This was a multiple-ascending dose, double-blind, placebo-controlled study evaluating efzofitimod in 37 patients with pulmonary sarcoidosis. The purpose of this study was to determine if efzofitimod was safe and tolerable in patients with pulmonary sarcoidosis who underwent a protocol-guided oral corticosteroid taper. This study was also designed to explore whether efzofitimod had the potential to reduce oral corticosteroid use, as well as the effects efzofitimod may have had on pulmonary sarcoidosis by measures of lung function, health-related quality of life assessments and disease biomarkers.","ATYR1923-C-003: Investigational Trial of ATYR1923 for the Treatment of COVID-19 Related Severe Respiratory Complications In January 2021, we announced positive data from our Phase 2 clinical trial evaluating efzofitimod in patients with COVID-19 related severe respiratory complications. The trial was a randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of efzofitimod as compared to placebo in 32 hospitalized COVID-19 patients with severe respiratory complications who did not require mechanical ventilation. Patients enrolled in the trial were randomized 1:1:1 to receive a single intravenous dose of either 1.0 or 3.0 mg/kg efzofitimod or placebo. Patients were followed for 60 days post treatment.","ACTRN12617001446358: EVALUATION OF THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS ATYR1923 IN HEALTHY VOLUNTEERS In the second quarter of 2018 we announced positive data from our Phase 1 clinical trial of efzofitimod. This first-in-human, randomized, double-blind, placebo-controlled study was designed to investigate the safety, tolerability, immunogenicity and pharmacokinetics of intravenous efzofitimod in healthy volunteers. The Phase 1 study enrolled 36 healthy volunteers who were randomized to one of six cohorts and received a single infusion of intravenous efzofitimod or placebo. Doses of efzofitimod ranged from 0.03 mg/kg up to 5.0 mg/kg. The results indicate that the drug was generally well-tolerated at all dose levels tested, with no significant adverse events or induction of anti-drug antibodies observed following efzofitimod dosing or throughout the one-month follow-up period.","EVALUATION OF THE SAFETY, PHARMACOKINETICS AND IMMUNOGENICITY OF KRP-R120 IN HEALTHY JAPANESE VOLUNTEERS Kyorin Pharmaceutical conducted a Phase 1 clinical trial of efzofitimod, which investigated the safety, PK and immunogenicity of efzofitimod (known as KRP-R120 in Japan) in 32 healthy Japanese volunteers. In this study, efzofitimod was observed to be generally safe and well-tolerated with no drug-related serious adverse events and PK findings were consistent with previous studies of efzofitimod."]
Leadership
Sanjay S. Shukla, M.D., M.S. (President and CEO, Dr. Shukla has served as our President and Chief Executive Officer and as a director since November 2017. He has extensive experience in clinical development and medical affairs, previously serving as Vice President and Global Head of Integrated Medical Services for Novartis.), Brandon Yaras (Chief Financial Officer, Mr. Yaras has served as our Chief Financial Officer since October 2026 and has nearly 20 years of corporate finance and accounting experience.), Lisa Carey (VP, Clinical Operations, Ms. Carey has over 30 years of clinical operations experience and has overseen the company’s clinical programs since May 2023.), Danielle Campbell (VP, Human Resources, Ms. Campbell has served as our Vice President, Human Resources since December 2021 and has a strong background in human resources and facilities management.), Leslie Nangle, Ph.D. (VP, Research, Dr. Nangle has over 20 years of research experience and has been with aTyr since 2007, focusing on extracellular tRNA synthetases.)

Verified data last updated:

Recent filings